Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 5/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | REN | P00797 | 5/20 | 0.41 |
| ▸ | CTSD | P07339 | 2/20 | 0.41 |
| ▸ | CTSE | P14091 | 2/20 | 0.41 |
| ▸ | PGC | P20142 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL23830443 | 0.86 | SLC6A2 (0.61) | SLC6A2SLC6A4SLC6A3CYP1A2CYP3A4 | |
| Trifluoroacetic Acid SCHEMBL17542042 | 0.86 | SLC6A2 (0.53) | SLC6A2SLC6A4SLC6A3CYP1A2CYP3A4 | |
| Trifluoroacetic Acid SCHEMBL3171388 | 0.85 | GBA1 (0.53) | KCNH2 | |
| Trifluoroacetic Acid SCHEMBL30548820 | 0.85 | SLC6A4 (0.47) | SLC6A2SLC6A4SLC6A3CYP1A2CYP3A4 | |
| SCHEMBL3914733 | 0.83 | SLC6A4 (0.50) | SLC6A2SLC6A4SLC6A3CYP3A4CYP2D6 | |
| Trifluoroacetic Acid SCHEMBL2301821 | 0.82 | SLC6A4 (0.43) | SLC6A2SLC6A4SLC6A3CYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL29090963 | 0.82 | SLC6A4 (0.49) | SLC6A2SLC6A4SLC6A3CYP3A4CYP2D6 | |
| Trifluoroacetic Acid SCHEMBL23455778 | 0.76 | HTR3A (0.50) | SLC6A2SLC6A3 | |
| Trifluoroacetic Acid SCHEMBL18497346 | 0.76 | SLC6A2 (0.43) | SLC6A2SLC6A4SLC6A3CYP1A2CYP3A4 | |
| Trifluoroacetic Acid SCHEMBL18863016 | 0.76 | EPHX2 (0.54) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7288537-B2 | Azetidine derivatives as CCR-3 receptor antagonists | NOVARTIS AG (CH) | 2007-10-30 | — | — | US | disclosed |
| EP-1663966-B1 | 1,3-DISUBSTITUTED AZETIDINE DERIVATIVES FOR USE AS CCR-3 RECEPTOR ANTAGONISTS IN THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISEASES | NOVARTIS AG (CH) | 2007-06-20 | — | — | EP | disclosed |
| US-20070043013-A1 | 1,3 Disubstituted azetidine derivatives for use as ccr-3 receptor antagonists in the treatment of inflammatory and allergic diseases | LE GRAND DARREN M | 2007-02-22 | — | — | US | disclosed |
| CN-1849302-A | 1, 3-disubstituted azetidine derivatives useful as CCR-3 receptor antagonists in the treatment of inflammatory and allergic diseases | NOVARTIS AG (CH) | 2006-10-18 | — | — | CN | disclosed |
| EP-1663966-A1 | 1,3-DISUBSTITUTED AZETIDINE DERIVATIVES FOR USE AS CCR-3 RECEPTOR ANTAGONISTS IN THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISEASES | Novartis AG (CH) | 2006-06-07 | — | — | EP | disclosed |
| US-20050222118-A1 | Azetidine derivatives as ccr-3 receptor antagonists | NOVARTIS AG (CH) | 2005-10-06 | — | — | US | disclosed |
| CN-1638761-A | Azetidine derivatives as CCR-3 receptor antagonists | NOVARTIS AG (CH) | 2005-07-13 | — | — | CN | disclosed |
| WO-2005026113-A1 | 1, 3-DISUBSTITUTED AZETIDINE DERIVATIVES FOR USE AS CCR-3 RECEPTOR ANTAGONISTS IN THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISEASES | NOVARTIS AG (CH) | 2005-03-24 | — | — | WO | disclosed |
| EP-1487435-A1 | AZETIDINE DERIVATIVES AS CCR-3 RECEPTOR ANTAGONISTS | Novartis AG (CH) | 2004-12-22 | — | — | EP | disclosed |
| WO-2003077907-A1 | AZETIDINE DERIVATIVES AS CCR-3 RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2003-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222118-A1 | Azetidine derivatives as ccr-3 receptor antagonists | CCR3, CCR1, CCR9 | SLC6A2 1453/4885SLC6A4 1121/4885SLC6A3 372/4885 |
| US-20070043013-A1 | 1,3 Disubstituted azetidine derivatives for use as ccr-3 receptor antagonists in the treatment of inflammatory and allergic diseases | CCR1, CCR3, CCR9 | SLC6A2 3873/4885SLC6A4 3261/4885SLC6A3 1927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.